Alex­ion cau­tious­ly steps over to the C6 path­way with an ear­ly-stage de­vel­op­ment deal tied to buy­out op­tion

Af­ter build­ing up its ex­per­tise in the C5 com­ple­ment path­way through its work on Soliris, Alex­ion $ALXN is now on a low-bud­get jour­ney to see what an up­start biotech can do with C6. And if it looks good, Alex­ion says it has an op­tion to buy them out.

The biotech is Com­ple­ment Phar­ma, which is now part­ner­ing with Alex­ion on the pre­clin­i­cal C6 com­ple­ment in­hibitor CP010. The drug has po­ten­tial in a va­ri­ety of neu­rode­gen­er­a­tive con­di­tions, Alex­ion’s top re­searcher John Orloff says, and they’re pay­ing up to €14 mil­lion in mile­stones to fund the work through Phase Ib.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER